The Significance of Screening Questionnaire in the Evaluation of Age-Related Macular Risk Degeneration Development
https://doi.org/10.18008/1816-5095-2019-4-501-507
Abstract
Aim: to evaluate the diagnostic value and objectification of the STARS questionnaire in the evaluation of risk of age-related macular degeneration (AMD) development.
Patients and methods. 104 patients (206 eyes) 40 males (32.3 %), 84 women (67.7 %), who filled the self-administered STARS screening questionnaire, were enrolled in the study. All patients were referred without suspicion or established diagnosis of AMD of any other retinal pathology. Optical coherent tomography (OCT) and macular pigment optical density (MPOD) were carried out in order to objectify questionnaire score points and retinal structural changes.
Results. The significant difference was found between patient without AMD and those with newly established AMD diagnosis not only in questionnaire score but also in some structural changes indicators: mean retinal thickness, foveal retinal thickness by OCT (<0.05). The direct correlation between increase in questionnaire points and estimate AMD stage by AREDS was found as well as the direct correlation between questionnaire score points and risk of AMD development, newly established AMD diagnosis, maximal macular pigment optical density (MPOD), mean macular pigment optical density and central retinal thickness. The area under ROC-curve was 0.62.
Conclusion. STARS is a new, simple, self-administered questionnaire which accurately distinguishes AMD development and progression risk groups and can be recommended for routine use in every day practice.
About the Authors
L. A. Kochmasheva
Sverdlovsk Regional Clinical Hospital № 1
Russian Federation
Russian Federation
head of the department of counselling diagnostic clinic
Volgogradskaya str., 185, Yekaterinburg, 620016, Russian Federation
Z. Yu. Prokhorova
Sverdlovsk Regional Clinical Hospital № 1
Russian Federation
Russian Federation
Ophthalmologist
Volgogradskaya str., 185, Yekaterinburg, 620016, Russian Federation
A. G. Grinev
Sverdlovsk Regional Clinical Hospital № 1
Russian Federation
Russian Federation
МD, head of the department of ophthalmology
Volgogradskaya str., 185, Yekaterinburg, 620016, Russian Federation
References
1. Vlasova I.A., Agapitov A.E., Gubin G.I., Gubin D.G. Preventive medicine: subject and content (lecture 2). Siberian Medical Journal = Sibirskij medicinskij zhurnal. 2005;55(6):94–96 (In Russ.)
2. Wilson J.M.G., Jungner G. Principles and practice of screening for disease. WHO Chronicle Geneva: World Health Organization. 1968.22(11):473. Public Health Papers, #34.
3. Congdon N., et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485. DOI: 10.1001/ar‑chopht.122.4.477
4. Colijn J.M. Prevalence of Age‑Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017;124:1753–1763. DOI: 10.1016/j.ophtha.2017.05.035
5. https://eyepress.ru/periodical.aspx?11 Federal Clinical Recommendations. Association of Ophthalmologists (In Russ.)
6. Neroev V.V. Russian observational epidemiological non‑interventional study of patients with a wet form of age‑related macular degeneration. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2011;4(2):4–9 (In Russ.)
7. Evans J.R., Fletcher A.E., Wormald R.P.L. Causes of visual impairment in people aged 75 years and older in Britain: an add on study to the MRC Trial of Assessment and management of older people in the community. Br J Ophthalmol. 2004;88:365–370. DOI: 10.1136/bjo.2003.019927
8. Friedman D.S., O’Colmain B.J., Munoz B., et al. Prevalence of age‑related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572. DOI: 10.1001/archopht.122.4.564
9. Lim L.S., Mitchell P., Seddon J.M. Age‑related macular degeneration. Lancet. 2012;379:1728–1738. DOI: 10.1016/S0140‑6736(12)60282‑7
10. Brown G.C., Brown M.M., Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age–related macular degeneration. Can. J. Ophthalmol. 2000;35(3):127–133.
11. Hart P.M., Chakravarthy U., Stevenson M.R. Questionnaire based survey on the importance of quality of life measures in ophthalmic practice. Eye. 1998;12(Pt 1):124–126. DOI: 10.1038/eye.1998.20
12. Linder M., Chang T.S., Scott I.U., Hay D., Chambers K., Sibley L.M., et al. Validity of the visual function index (VF–14) in patients with retinal disease. Arch. Ophthalmol. 1999;117(12):1611–1616. DOI: 10.1001/archopht.117.12.1611
13. McClure M.E., Hart P.M., Jackson A.J., Stevenson M.R., Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability. Br. J. Ophthalmol. 2000;84:244–250. DOI: 10.1136/bjo.84.3.244
14. Mills R.P. Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Trans. Am. Ophthalmol. Soc. 1998;96:753.
15. Yelin E. Measuring Functional Capacity of Persons with Disabilities in Light of Emerging Demands in the Workplace. NAP. 1999. Available from:
16. https://www.ncbi.nlm.nih.gov/books/NBK230769/
17. Brown G.C., Brown M.M., Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age–related macular degeneration. Can. J. Ophthalmol. 2000;35(3):127–133.
18. Hazel C.A., Petre K.L., Armstrong R.A., Benson M.T., Frost N.A. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest.Ophthalmol. Vis. Sci. 2000;41(6):1309–1315.
19. Resnikoff S., Pascolini D., Etya’ale D. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851. DOI: S0042‑96862004001100009
20. Wang F., Tielsch J.M., Ford D.E., Quigley H.A., Whelton P.K. Evaluation of screening schemes for eye disease in a primary care setting. Ophthalmic Epidemiol. 1998 Jun;5(2):69–82. DOI: 10.1076/opep.5.2.69.1575
21. Heesterbeek T.J., de Jong E.K., Acar I.E., Groenewoud J.M.M., Liefers B., Sánchez C.I., Peto T., Hoyng C.B., Pauleikhof D., Hense H.W., den Hollander A.I. Genetic risk score has added value over initial clinical grading stage in predicting disease progression in age‑related macular degeneration. Sci Rep. 2019;9:6611. DOI: 10.1038/s41598‑019‑43144‑3
22. Seddon J.M., Reynolds R., Yu Y., Daly M.J., Rosner B. Risk models for progression to advanced age‑related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118:2203–2211. DOI: 10.1016/j.ophtha.2011.04.029
23. Buitendijk G.H., Rochtchina E., Myers C. Prediction of age‑related macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology. 2013; 120: 2644–2655. DOI: 10.1016/j.ophtha.2013.07.053
24. Seddon J.M., Reynolds R., Yu Y., Rosner B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. JAMA Ophthalmol. 2013;131:448–455. DOI: 10.1001/jamaophthalmol.2013.2578
25. Chiu C.J., Mitchell P., Klein R. A risk score for the prediction of advanced agerelated macular degeneration: development and validation in 2 prospective cohorts. Ophthalmology. 2014;121:1421–1427. DOI: 10.1016/j.ophtha.2014.01.016
26. Yu Y. Prospective Assessment of Genetic Effects on Progression to Different Stages of Age‑Related Macular Degeneration Using Multistate Markov Models; IOVS. 2012;53(3):1548–1556 DOI: 10.1167/iovs.11‑8657
27. Seddon J.M. et al. Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes. JAMA Ophthalmol. 2013;131(4):448–455 DOI: 10.1001/jamaophthalmol.2013.2578
28. Seddon J.M. The US twin study of age‑related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 23(3): 321–327. DOI: 10.1001/archopht.123.3.321
29. Seddon J.M., Silver R.E., Kwong M., Rosner B. Risk prediction for progression of macular degeneration: 10 common and rare genetic variants, demographic, environmental, and macular covariates. Invest Ophthalmol Vis Sci. 2015;56:2192–2202. DOI: 10.1167/iovs.14‑15841
30. Kulik A.V., Bogomolov A.V. Method for predicting the risk of macular degeneration. Medical News of North Caucasus = Medicinskij vestnik Severnogo Kavkaza. 2016;11(3):448–445 (In Russ.). DOI: 10.14300/mnnc.2016.11101
31. Delcourt C., Souied E., Sanchez A., Bandello F.; STARS Survey Group. Development and Validation of a Risk Score for Age‑Related Macular Degeneration: The STARS Questionnaire. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6399–6407. DOI: 10.1167/iovs.17‑21819
Review
For citations:
Kochmasheva L.A., Prokhorova Z.Yu., Grinev A.G. The Significance of Screening Questionnaire in the Evaluation of Age-Related Macular Risk Degeneration Development. Ophthalmology in Russia. 2019;16(4):501-507. (In Russ.) https://doi.org/10.18008/1816-5095-2019-4-501-507
Views:
1779
Email this article 